newsfilter
← Latest News
GlobeNewswire·

AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention

OCALA, Fla., June 13, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vir